Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says
geralt / Pixabay

Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says

According to a story from BNN Bloomberg, Novartis AG, a drug company that is nearing the completion of the development of a potentially groundbreaking new gene therapy for spinal muscular…

Continue Reading Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says
Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy
Pexels / Pixabay

Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

According to a story from globenewswire.com, the biotechnology company Biogen recently released data from an open label study that was testing the company's spinal muscular atrophy drug nusinersen (marketed as…

Continue Reading Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy
Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy
skeeze / Pixabay

Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy

According to a story from inpublic.globenewswire.com, the Novartis company AveXis has released interim data from an ongoing Phase 3 clinical trial of Zolgensma, a gene therapy drug that is being…

Continue Reading Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy
Study Indicates Safety of New Potential Treatment for Swallowing Dysfunction in Kennedy Disease
source: pixabay.com

Study Indicates Safety of New Potential Treatment for Swallowing Dysfunction in Kennedy Disease

Kennedy disease or, Spinal and Bulbar Muscular Atrophy (SBMA) is a form of Spinal Muscular Atrophy (SMA). SBMA causes muscle weakness throughout the limbs which results in impaired mobility (typical…

Continue Reading Study Indicates Safety of New Potential Treatment for Swallowing Dysfunction in Kennedy Disease

Her Brother Participated in Trials for Vital Spinal Muscular Atrophy Drug, and Now She’s Denied Treatment Access

According to a story from mirror.co.uk, a five-month-old girl named Maryam Malji was diagnosed with spinal muscular atrophy, a progressive, degenerative disease that is ultimately fatal without treatment. Her brother…

Continue Reading Her Brother Participated in Trials for Vital Spinal Muscular Atrophy Drug, and Now She’s Denied Treatment Access

Massachusetts Proposes Installment Plan to Cover Cost of Gene Therapy for Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a genetic condition which affects between 10,000 and 25,000 in the United States. While rare, it is currently the leading genetic cause of infant mortality. But,…

Continue Reading Massachusetts Proposes Installment Plan to Cover Cost of Gene Therapy for Spinal Muscular Atrophy
Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy
qimono / Pixabay

Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy

According to a story from physiciansweekly.com, a recent report from the Institute for Clinical and Economic Review (ICER) suggests that, pending more data about overall price and longterm success rates,…

Continue Reading Nonprofit Organization Predicts Gene Therapy to be Most Cost Effective Treatment for Spinal Muscular Atrophy
Possible Treatment for Spinal Muscular Atrophy Gains PRIME Designation From the EMA
Belova59 / Pixabay

Possible Treatment for Spinal Muscular Atrophy Gains PRIME Designation From the EMA

According to a story from pm360online.com, the pharmaceutical company Roche recently announced that its investigational therapy risdiplam has awarded PRIME designation from the European Medicines Agency (EMA). The drug has…

Continue Reading Possible Treatment for Spinal Muscular Atrophy Gains PRIME Designation From the EMA

Experimental Gene Therapy for Type 1 Spinal Muscular Atrophy Gets Priority Review

According to a story from BioPortfolio, the drug developer Novartis recently announced that the US Food and Drug Administration (FDA) has granted the company's investigational gene therapy AVXS-101, also known…

Continue Reading Experimental Gene Therapy for Type 1 Spinal Muscular Atrophy Gets Priority Review
A Woman With Spinal Muscular Atrophy is Fighting for Access to the Therapy That Could Save Her
source: pixabay.com

A Woman With Spinal Muscular Atrophy is Fighting for Access to the Therapy That Could Save Her

According to a story from MarketWatch, Annie Wilson was diagnosed with spinal muscular atrophy when she was only six months old. With no real treatment options available, doctors told her…

Continue Reading A Woman With Spinal Muscular Atrophy is Fighting for Access to the Therapy That Could Save Her

Cure SMA’s Annual SMA Conference

  • Post author:
  • Post category:

The 2018 Annual SMA Conference This conference will bring together researchers, medical experts, scientists, and patient families to build community, learn, collaborate, and network. The conference consists of two parallel…

Continue Reading Cure SMA’s Annual SMA Conference